Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Result
of your search per sponsor: Pfizer Inc
Woman and Man Max 99 years
Pfizer Inc. - La Jolla laboratories
Update Il y a 4 ans
A randomized phase 2 study of the anti-angiogenesis agent AG-013736 in combination with gemcitabine in patients with chemotherapy-naïve advanced pancreatic cancer preceded by a phase 1 portion
Determine whether the overall survival of the combination of AG-013736 and gemcitabine is superior to that of gemcitabine alone in patients who have advanced pancreatic cancer that has not been previo...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Pfizer Inc.235 East 42nd Street, New York, NY 10017
Update Il y a 4 ans
A Phase 2A, Randomized, Placebo-controlled, Parallel group, Multiple-dose study to evaluate the Efficacy, Safety and Tolerability of 12-week oral administration of PF-00734200 tablets to subjects with Type 2 Diabetes Mellitus on stable treatment with Metformin
To compare the effect of multiple oral doses of PF 00734200 tablet versus placebo on change from baseline to 12 weeks of Hb A1c levels and evaluate dose response in subjects with T2DM on a stable dose...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Pfizer Inc
Update Il y a 4 ans
A medical research study to evaluate the safety and effectiveness of an investigational medication for rheumatoid arthritis
To evaluate the efficacy of PF-06651600 at 8 weeks in subjects with moderate to severe active RA.
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Pfizer Inc.235 East 42nd Street, New York, NY 10017
Update Il y a 4 ans
A PHASE 3 RANDOMIZED, DOUBLE-BLIND, ACTIVE-CONTROLLED, MULTICENTER STUDY OF THE LONG-TERM SAFETY AND EFFICACY OF SUBCUTANEOUS ADMINISTRATION OF TANEZUMAB IN SUBJECTS WITH OSTEOARTHRITIS OF THE HIP OR KNEE
- Characterize the long-term risk of joint safety events in subjects with osteoarthritis of the knee or hip who receive tanezumab 2.5 mg or tanezumab 5 mg SC versus NSAID treatment (naproxen 500 mg BI...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Pfizer Inc, 235 East 42nd Street, New York, New York 10017, USA
Update Il y a 4 ans
A study of oral CP-690,550 as an induction therapy in subjects with moderate to severe ulcerative colitis
To demonstrate the efficacy of tofacitinib in inducing remission in subjects with moderately to severely active UC.
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Pfizer Inc 235 East 42nd Street, New York, NY10017
Update Il y a 4 ans
A 16 WEEK OPEN-LABEL OUTPATIENT, RANDOMIZED, PARALLEL STUDY ASSESSING THE IMPACT OF TWO DIFFERENT INITIAL DOSE PRESCRIPTIONS FOR DRY POWDER INHALED INSULIN (EXUBERA®) ON GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES MELLITUS WHO ARE POORLY CONTROLLED ON A COMBINATION OF TWO OR MORE ORAL AGENTS
The primary objective of this study is to assess whether a simple initial dose prescription of inhaled insulin (Exubera) achieves glycemic control (HbA1c) after 16 weeks that is noninferior compared t...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Pfizer Inc.235 East 42nd Street, New York, NY 10017
Update Il y a 4 ans
RANDOMIZED, DOUBLE-BLIND, 6-WEEK STUDY OF PREGABALIN IN SUBJECTS WITH RESTLESS LEG SYNDROME
To characterize the dose-response relationship for pregabalin in the treatment of RLS symptoms in subjects with idiopathic RLS using the IRLS scale.
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Pfizer Inc
Update Il y a 4 ans
A 1-YEAR, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CP-945,598 IN THE TREATMENT OF OVERWEIGHT, ORAL AGENT-TREATED SUBJECTS WITH TYPE 2 DIABETES MELLITUS
Determine in overweight/obese subjects with type 2 diabetes mellitus whether body weight can be made significantly lower by treatment with CP 945,598 compared to treatment with placebo.
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Pfizer Inc.235 East 42nd Street, New York, NY 10017
Update Il y a 4 ans
A Phase 1 trial of pf‑03084014 in patients with advanced solid tumor malignancy and t‑cell acute lymphoblastic leukemia/lymphoblastic lymphoma
Phase 1a Primary Objectives 1. To determine the maximum tolerated dose (MTD) of PF-03084014 when administered twice daily for 21 days alone in patients with advanced malignancies (encompassing adva...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Pfizer Inc.235 East 42nd Street, New York, NY 10017
Update Il y a 4 ans
Study with investigational drug PF-06463922 and comparator crizotinib in patients with a specific type of advanced lung cancer
- To demonstrate that lorlatinib as a single agent (Arm A) is superior to crizotinib alone (Arm B) in prolonging progression-free survival (PFS) in advanced ALK-positive NSCLC patients who are treatme...
Country
None
organs
None
Specialty
None
unknown
More information
Previous
3
4
5
6
7
8
9
10
11
12
Next